Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 361 to 370 of 875

TitleReference numberPublishedLast updated
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Upadacitinib for treating moderate rheumatoid arthritisTA744
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740

Results per page

  1. 10
  2. 25
  3. 50
  4. All